Aspira Pathlab Diagnostics Ltd vs Fortis Healthcare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Aspira Pathlab & Diagnostics Ltd is ₹ 143.34 as of 29 Sep 10:20 . The P/E Ratio of Aspira Pathlab & Diagnostics Ltd changed from 43.3 on March 2025 to 0 on March 2026 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Fortis Healthcare Ltd changed from 53 on March 2024 to 57.6 on March 2026 . This represents a CAGR of 1.40% over 6 years The Market Cap of Aspira Pathlab & Diagnostics Ltd changed from ₹ 31.91 crore on March 2024 to ₹ 0 crore on March 2026 . This represents a CAGR of -100.00% over 6 yearsThe Market Cap of Fortis Healthcare Ltd changed from ₹ 31700 crore on March 2024 to ₹ 59988 crore on March 2026 . This represents a CAGR of 11.22% over 6 years The revenue of Aspira Pathlab & Diagnostics Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Fortis Healthcare Ltd for the Jun '26 is ₹ 2573 crore as compare to the Mar '26 revenue of ₹ 2375 crore. This represent the growth of 8.34% The ebitda of Aspira Pathlab & Diagnostics Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Fortis Healthcare Ltd for the Jun '26 is ₹ 565.5 crore as compare to the Mar '26 ebitda of ₹ 530.45 crore. This represent the growth of 6.61% The net profit of Aspira Pathlab & Diagnostics Ltd changed from ₹ 0.05 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of -100.00% The net profit of Fortis Healthcare Ltd changed from ₹ 173.98 crore to ₹ 272.8 crore over 9 quarters. This represents a CAGR of 22.13% The Dividend Payout of Aspira Pathlab & Diagnostics Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Fortis Healthcare Ltd changed from 78.45 % on March 2023 to 32.78 % on March 2026 . This represents a CAGR of -19.60% over 4 years .

About Aspira Pathlab & Diagnostics Ltd

Aspira Pathlab & Diagnostics Limited (ASDL) was incorporated in July, 1973.
ASDL is a leading pathology specialist, with Pan-India presence.
It offer pathology and diagnostic services to individual patients, hospitals, other healthcare providers, and businesses.
The Company, with a wider presence in Maharashtra India, enjoys a loyal customer base, that reflects on its strength as a brand, providing superior diagnostic testing and services. Presently, Company is engaged into the business of running, owning, managing and administering Diagnostics Centers.
Its principal activities consist of pathology investigation services, radiology investigation services and other related healthcare services at Diagnostic Centres in Mumbai. ASDL ideology is founded on technological supremacy, patient centric approach, and dependable diagnostic results.

About Fortis Healthcare Ltd

Fortis Healthcare Limited (FHL) is one of the largest healthcare services providers in India with 27 hospitals, ~4,750+ operational beds and 400+ diagnostics centres as of 31 March, 2025.
The Company offers a full spectrum of integrated healthcare services ranging from clinics to quaternary care facilities and a wide range of ancillary services to patients in areas such as Cardiac Care, Orthopedics, Neurosciences, Oncology, renal care, Gastroenterology and Mother and Child care..
They are delivering quality healthcare services to patients in modern facilities using advanced technology. SRL Limited, a subsidiary of FHL is primarily involved in providing diagnostics services and is amongst the leading diagnostics chains in India with a significant market share in the organized diagnostics segment.

FAQs for the comparison of Aspira Pathlab & Diagnostics Ltd and Fortis Healthcare Ltd

Which company has a larger market capitalization, Aspira Pathlab & Diagnostics Ltd or Fortis Healthcare Ltd?

Market cap of Aspira Pathlab & Diagnostics Ltd is 129 Cr while Market cap of Fortis Healthcare Ltd is 54,356 Cr

What are the key factors driving the stock performance of Aspira Pathlab & Diagnostics Ltd and Fortis Healthcare Ltd?

The stock performance of Aspira Pathlab & Diagnostics Ltd and Fortis Healthcare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aspira Pathlab & Diagnostics Ltd and Fortis Healthcare Ltd?

As of October 25, 2026, the Aspira Pathlab & Diagnostics Ltd stock price is INR ₹126.05. On the other hand, Fortis Healthcare Ltd stock price is INR ₹720.0.

How do dividend payouts of Aspira Pathlab & Diagnostics Ltd and Fortis Healthcare Ltd compare?

To compare the dividend payouts of Aspira Pathlab & Diagnostics Ltd and Fortis Healthcare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.